Salicylanilide pyrazinoates inhibit in vitro multidrug-resistant Mycobacterium tuberculosis strains, atypical mycobacteria and isocitrate lyase

European Journal of Pharmaceutical Sciences

Volumn 53, Issue 1, 2014, Pages 1-9

  Krátký, Martin ^a   Vinšová, Jarmila ^a   Novotná, Eva ^a   Stolaříková, Jiřina ^b  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b Zdravotniho ustavu se sidlem v Ostrave   (Czech Republic)

Author keywords

Antimycobacterial activity; In vitro activity; Isocitrate lyase inhibition; Multidrug resistant tuberculosis; Pyrazine 2 carboxylic acid ester; Salicylanilide ester

Indexed keywords

AMINOSALICYLIC ACID; ANTIMYCOBACTERIAL AGENT; BACTERIAL ENZYME; ISOCITRATE LYASE; ISONIAZID; PYRAZINAMIDE; PYRAZINOIC ACID DERIVATIVE; SALICYLANILIDE DERIVATIVE; SALICYLANILIDE PYRAZINOATE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; ATYPICAL MYCOBACTERIUM; BACTERIAL STRAIN; CONCENTRATION RESPONSE; CROSS RESISTANCE; CYTOTOXICITY; DRUG POTENTIATION; ENZYME INHIBITION; HYDROLYSIS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM AVIUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL;

ANTIMYCOBACTERIAL ACTIVITY; IN VITRO ACTIVITY; ISOCITRATE LYASE INHIBITION; MULTIDRUG-RESISTANT TUBERCULOSIS; PYRAZINE-2-CARBOXYLIC ACID ESTER; SALICYLANILIDE ESTER;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ISOCITRATE LYASE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NONTUBERCULOUS MYCOBACTERIA; PYRAZINAMIDE; SALICYLANILIDES;

EID: 84891593361     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.12.001     Document Type: Article

References (56)

1. D.R. Appleton, A.N. Pearce, and B.R. Copp Anti-Tuberculosis natural products: synthesis and biological evaluation of pyridoacridine alkaloids related to ascididemin Tetrahedron 66 2010 4977 4986
2. K.E. Bergmann, M.H. Cynamon, and J.T. Welch Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters J. Med. Chem. 39 1996 3394 3400 (Pubitemid 26322865)
3. H.I. Boshoff, V. Mizrahi, and C.E. Barry Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I J. Bacteriol. 184 2002 2167 2172 (Pubitemid 34259666)
4. S.T. Byrne, S.M. Denkin, and Y. Zhang Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis J. Antimicrob. Chemother. 59 2007 313 316 (Pubitemid 47072074)
5. J.A. Caminero Extensively drug-resistant tuberculosis: is its definition correct? Eur. Respir. J. 32 2008 1413 1415
6. J.A. Caminero, G. Sotgiu, A. Zumla, and G.B. Migliori Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis Lancet Infect. Dis. 10 2010 621 629
7. T.J.R. Cheng, Y.T. Wu, S.T. Yang, K.H. Lo, S.K. Chen, Y.H. Chen, W.I. Huang, C.H. Yuan, C.W. Guo, L.Y. Huang, K.T. Chen, H.W. Shih, Y.S.E. Cheng, W.C. Cheng, and C.H. Wong High-throughput identification of antibacterials against methicillin-resistant Staphylococcus aureus (MRSA) and the transglycosylase Bioorg. Med. Chem. 18 2010 8512 8529
8. J.L. Cook Nontuberculous mycobacteria: opportunistic environmental pathogens for predisposed hosts Br. Med. Bull. 96 2010 45 59
9. M.H. Cynamon, S.P. Klemens, T.S. Chou, R.H. Gimi, and J.T. Welch Antimycobacterial activity of a series of pyrazinoic acid esters J. Med. Chem. 35 1992 1212 1215
10. M.H. Cynamon, R. Gimi, F. Gyenes, C.A. Sharpe, K.E. Bergmann, H.J. Han, L.B. Gregor, R. Rapolu, G. Luciano, and J.T. Welch Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity J. Med. Chem. 38 1995 3902 3907
11. L.P.S. de Carvalho, C.M. Darby, K.Y. Rhee, and C. Nathan Nitazoxanide disrupts membrane potential and intrabacterial pH homeostasis of Mycobacterium tuberculosis ACS Med. Chem. Lett. 2 2011 849 854
12. G.H. Dixon, and H.L. Kornberg Assay methods for key enzymes of the glyoxylate cycle Biochem. J. 72 1959 P3
13. L.G. Dover, and G.D. Coxon Current status and research strategies in tuberculosis drug development J. Med. Chem. 54 2011 6157 6165
14. R.G. Ducati, A. Ruffino-Netto, L.A. Basso, and D.S. Santos The resumption of consumption. A review on tuberculosis Mem. Inst. Oswaldo Cruz 101 2006 697 714
15. J.M. Férriz, K. Vávrová, F. Kunc, A. Imramovský, J. Stolaříková, E. Vavří ková, and J. Vinšová Salicylanilide carbamates: antitubercular agents active against multidrug-resistant Mycobacterium tuberculosis strains Bioorg. Med. Chem. 18 2010 1054 1061
16. A. Fomovska, R.D. Wood, E. Mui, J.P. Dubey, L.R. Ferreira, M.R. Hickman, P.J. Lee, S.E. Leed, J.M. Auschwitz, W.J. Welsh, C. Sommerville, S. Woods, C. Roberts, and R. McLeod Salicylanilide inhibitors of Toxoplasma gondii J. Med. Chem. 55 2012 8375 8391
17. A.L. Garner, C. Gloeckner, N. Tricoche, J.S. Zakhari, M. Samje, F. Cho-Ngwa, S. Lustigman, and K.D. Janda Design, synthesis, and biological activities of closantel analogues: structural promiscuity and its impact on Onchocerca volvulus J. Med. Chem. 54 2011 3963 3972
18. K.M. Huttunen, and J. Rautio Prodrugs - an efficient way to breach delivery and targeting barriers Curr. Top. Med. Chem. 11 2011 2265 2287
19. P. Jureen, J. Werngren, J.C. Toro, and S. Hoffner Pyrazinamide resistance and pncA Gene Mutations in Mycobacterium tuberculosis Antimicrob. Agents Chemother. 52 2008 1852 1854 (Pubitemid 351614686)
20. M. Krátký, and J. Vinšová Salicylanilide ester prodrugs as potential antimicrobial agents - a review Curr. Pharm. Des. 17 2011 3494 3505
21. M. Krátký, and J. Vinšová Advances in mycobacterial isocitrate lyase targeting and inhibitors Curr. Med. Chem. 19 2012 6126 6137
22. M. Krátký, J. Vinšová, V. Buchta, K. Horvati, S. Bösze, and J. Stolaříková New amino acid esters of salicylanilides active against MDR-TB and other microbes Eur. J. Med. Chem. 45 2010 6106 6113
23. M. Krátký, J. Vinšová, and V. Buchta In vitro antibacterial and antifungal activity of salicylanilide pyrazine-2-carboxylates Med. Chem. 8 2012 732 741
24. M. Krátký, J. Vinšová, E. Novotná, J. Mandíková, V. Wsól, F. Trejtnar, V. Ulmann, J. Stolaříková, S. Fernandes, S. Bhat, and J.O. Liu Salicylanilide derivatives block Mycobacterium tuberculosis through inhibition of isocitrate lyase and methionine aminopeptidase Tuberculosis 92 2012 434 439
25. M. Krátký, J. Vinšová, N.G. Rodriguez, and J. Stolaříková Antimycobacterial activity of salicylanilide benzenesulfonates Molecules 17 2012 492 503
26. M. Krátký, J. Vinšová, and J. Stolaříková Antimycobacterial assessment of salicylanilide benzoates including multidrug-resistant tuberculosis strains Molecules 17 2012 12812 12820
27. M. Krátký, J. Vinšová, E. Novotná, J. Mandíková, F. Trejtnar, and J. Stolaříková Antibacterial activity of salicylanilide 4-(trifluoromethyl)benzoates Molecules 18 2013 3674 3688
28. I.Y. Lee, T.D. Gruber, A. Samuels, M. Yun, B. Nam, M. Kang, K. Crowley, B. Winterroth, H.I. Boshoff, and C.E. Barry Structure-activity relationships of antitubercular salicylanilides consistent with disruption of the proton gradient via proton shuttling Bioorg. Med. Chem. 21 2013 114 126
29. P. Lobue, and D. Menzies Treatment of latent tuberculosis infection: an update Respirology 15 2010 603 622
30. P. Lu, A.C. Haagsma, H. Pham, J.J. Maaskant, S. Mol, H. Lill, and D. Bald Pyrazinoic acid decreases the proton motive force, respiratory ATP synthesis activity, and cellular ATP levels Antimicrob. Agents Chemother. 55 2011 5354 5357
31. D.A. Mitchison, and P.B. Fourie The near future: improving the activity of rifamycins and pyrazinamide Tuberculosis 90 2010 177 181
32. E.J. Muñoz-Elías, and J.D. McKinney Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence Nat. Med. 11 2005 638 644 (Pubitemid 40868304)
33. S.C. Ngo, O. Zimhony, W.J. Chung, H. Sayahi, W.R. Jacobs, and J.T. Welch Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs Antimicrob. Agents Chemother. 51 2007 2430 2435 (Pubitemid 47047321)
34. A.C. Pinheiro, C.R. Kaiser, M.C.S. Lourenco, M.V.N. de Souza, S.M.S.V. Wardell, and J.L. Wardell Synthesis and in vitro activity towards Mycobacterium tuberculosis of l-serinyl ester and amino derivatives of pyrazinoic acid J. Chem. Res. 3 2007 180 184
35. S.P.S. Rao, S. Alonso, L. Rand, T. Dick, and K. Pethe The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis Proc. Natl. Acad. Sci. USA 105 2008 11945 11950
36. C. Raynaud, M.A. Laneelle, R.H. Senaratne, P. Draper, G. Laneelle, and M. Daffel Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity Microbiology 145 1999 1359 1367 (Pubitemid 29294921)
37. H. Sayahi, O. Zimhony, W.R. Jacobs, A. Shekhtman, and J.T. Welch Pyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase I Bioorg. Med. Chem. Lett. 21 2011 4804 4807
38. H. Sayahi, K.M. Pugliese, O. Zimhony, W.R. Jacobs, A. Shekhtman, and J.T. Welch Analogs of the antituberculous agent pyrazinamide are competitive inhibitors of NADPH binding to M. tuberculosis fatty acid synthase I Chem. Biodivers. 9 2012 2582 2596
39. L.E. Seitz, W.J. Suling, and R.C. Reynold Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives J. Med. Chem. 45 2002 5604 5606 (Pubitemid 35424977)
40. W.L. Shi, X.L. Zhang, X. Jiang, H.M. Yuan, J.S. Lee, C.E. Barry, H.H. Wang, W.H. Zhang, and Y. Zhang Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis Science 333 2011 1630 1632
41. M.F. Simoes, E. Valente, M.J. Rodríguez Gómez, E. Anes, and L. Constantino Lipophilic pyrazinoic acid amide and ester prodrugs. Stability, activation and activity against M. tuberculosis Eur. J. Pharm. Sci. 37 2009 257 263
42. C.V. Smith, V. Sharma, and J.C. Sacchettini TB drug discovery: addressing issues of persistence and resistance Tuberculosis 84 2004 45 55 (Pubitemid 38082932)
43. R.J. Speirs, J.T. Welch, and M.H. Cynamon Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide Antimicrob. Agents Chemother. 39 1995 1269 1271
44. Z. Sun, and Y. Zhang Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide Antimicrob. Agents Chemother. 43 1999 537 542 (Pubitemid 29109516)
45. M.M. Wade, and Y. Zhang Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro J. Antimicrob. Chemother. 58 2006 936 941
46. WHO, 2010. Treatment of tuberculosis Guidelines Fourth edition [online]. [cited 30-10-2012]. < http://whqlibdoc.who.int/publications/2010/ 9789241547833-eng.pdf >.
47. WHO, 2011. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update [online]. [cited 29-10-2012]. < http://whqlibdoc.who.int/publications/2011/9789241501583-eng.pdf >.
48. S. Yamamoto, I. Toida, N. Watanabe, and T. Ura In Vitro antimycobacterial activities of pyrazinamide analogs Antimicrob. Agents Chemother. 39 1995 2088 2091
49. Y. Zhang, and D. Mitchison The curious characteristics of pyrazinamide: a review Int. J. Tuberc. Lung Dis. 7 2003 6 21 (Pubitemid 36427026)
50. Y. Zhang, and W.W. Yew Mechanisms of drug resistance in Mycobacterium tuberculosis Int. J. Tuberc. Lung Dis. 13 2009 1320 1330
51. Y. Zhang, M.M. Wade, A. Scorpio, H. Zhang, and Z.H. Sun Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid J. Antimicrob. Chemother. 52 2003 790 795 (Pubitemid 37407806)
52. Y. Zhang, H. Zhang, and Z. Sun Susceptibility of Mycobacterium tuberculosis to weak acids J. Antimicrob. Chemother. 52 2003 56 60 (Pubitemid 36850085)
53. H. Zhang, J.Y. Deng, L.J. Bi, Y.F. Zhou, Z.P. Zhang, C.G. Zhang, Y. Zhang, and X.E. Zhang Characterization of Mycobacterium tuberculosis nicotinamidase/pyrazinamidase FEBS J. 275 2008 753 762
54. Z.W. Zhu, L. Shi, X.M. Ruan, Y. Yang, H.Q. Li, S.P. Xu, and H.L. Zhu Synthesis and antiproliferative activities against Hep-G2 of salicylanide derivatives: potent inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase J. Enzym. Inhib. Med. Chem. 26 2011 37 45
55. O. Zimhony, C. Vilcheze, M. Arai, J.T. Welch, and W.R. Jacobs Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli Antimicrob. Agents Chemother. 51 2007 752 754 (Pubitemid 46185301)
56. M. Zimic, P. Fuentes, R.H. Gilman, H.A. Gutiérrez, D. Kirwan, and P. Sheen Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance Tuberculosis 92 2012 84 91